Healthcare Costs
-
Caught my eye, Drug Prices, Healthcare Costs, Inflation Reduction Act, Medicare Negotiation, Medicare Part DCaught my eye — 11/22/24
Read more: Caught my eye — 11/22/24As we look ahead to next week and Thanksgiving, I have to say thank you to you for subscribing and reading. I got the stuffing knocked out of me this summer but knowing that this group of subscribers hangs in there and continues to read is nice. As I look ahead to the next year,…
-
Caught my eye — 11/1/24
Read more: Caught my eye — 11/1/24As I write this, the elementary school across the street has Thriller playing at the 5th grade Halloween party happening in the parking lot. Things change and they stay the same. Not the worst reminder this week. Waiting. Payment rules expected from the Centers for Medicare & Medicaid Services plus maybe eventually the Medicare Transaction…
-
Biosimilars, Caught my eye, CMMI, Drug Prices, Employers, Healthcare Costs, Obesity, Pharmacy Benefit ManagersCaught my eye — 9/27/24
Read more: Caught my eye — 9/27/24If you haven’t trained your teams on Medicare Part D changes for 2025, hop to it. Or reach out to me. These are January 1 issues and we’re about to hit October…. Let me clear my throat. The STAT news breaking news headline read “Sanders says pharmacy benefit managers (PBMs) won’t penalize Novo for cutting…
-
340B, Caught my eye, Drug Prices, Healthcare Costs, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part DCaught my eye — 9/20/24
Read more: Caught my eye — 9/20/24Adding On. So glad to see this research from Avalere conducted on behalf of the Community Oncology Alliance (COA) on the impact of the Inflation Reduction Act (IRA) negotiation on Medicare Part B provider reimbursement. While in Medicare Part D, negotiated prices do not factor into Average Manufacturer Price, the legislation is silent on whether…
-
Caught my eye — 09/06/24
Read more: Caught my eye — 09/06/24The slight panic of 4 months left in the year is starting to hit but the amazing weather in the D.C. area made it seem just a bit less urgent. If you need any help with policy work these next few months or filling a speaking gig, I’m here for it. MedPAC was back this…
-
340B, Biosimilars, Drug Prices, Generics, Healthcare Costs, Medicare Advantage, Medicare Part D, ValueCaught my eye — 6/21/24
Read more: Caught my eye — 6/21/24You know it is hot when I say, “Let’s go for a walk” and my dog looks at me from the stop of the stairs and refuses to move. At 6:30 in the morning. I hope you’re feeling more motivated than he is. Same same, not different. Late last year, the Medicare prescription drug benefit…
-
Caught my eye — 6/14/24
Read more: Caught my eye — 6/14/24Summer vibes are real in the DC area this week with schools letting out and pool time kicking in. College wood bat baseball league games are on, and the summer night hang out is in full swing. I don’t know if it is my mood or the season or both, but things seem a little…
-
Caught my eye — 05/31/24
Read more: Caught my eye — 05/31/24Trying to change my view. I don’t know if it is summer malaise setting in or an existential crisis about the state of society, sometimes it is hard to tell. Earlier this week, Jessica Yellin of News Not Noise pointed out that a lot of articles are really negatively titled and it is driving a…
-
340B, Caught my eye, Drug Prices, Employers, Healthcare Costs, ICER, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Reference Pricing, ValueCaught my eye — 5/10/24
Read more: Caught my eye — 5/10/24Back to back. Arnold Ventures put out the latest anti-pharma talking points (h/t Brian Reid) and here were two back to back – Here’s the problem, it really isn’t about the cost of drugs. I mean you could take that drug price and reduce it 98% and the 25% cost share would still be too…
-
Affordable Care Act, Healthcare Costs, ICER, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part D, State-based ReformCaught my eye — 4/12/24
Read more: Caught my eye — 4/12/24PDAB-adieu. This week Governor Youngkin vetoed a bill that would have established a prescription drug affordability board (PDAB) in the state. The PDAB would have had authority over state-sponsored and state-regulated health plans. Younkin said that the PDAB would have determined drug availability solely on cost rather than unique patient needs and the opinions of…
Latest news
- AMP is WAC — 05/15/26
- AMP is WAC — 5/1/26
- AMP is WAC — 04/24/26
- AMP is WAC — 04/10/26
- AMP is WAC — 03/27/26
Categories
- 340B (66)
- Affordable Care Act (23)
- Alzheimer's (12)
- Biosimilars (33)
- Caught my eye (104)
- Cell and Gene (9)
- Chevron Deference (2)
- CMMI (31)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (60)
- Drug shortages (16)
- DTC (9)
- Employers (20)
- FDA (8)
- Generics (14)
- Health Equity (4)
- Healthcare Costs (42)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (70)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (26)
- Medicare Advantage (28)
- Medicare Negotiation (69)
- Medicare Part D (80)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (29)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (51)
- Preventative (5)
- Reference Pricing (27)
- State-based Reform (33)
- Supply Chain (9)
- Tariffs (3)
- Uncategorized (9)
- Utilization Management (14)
- Vaccines (10)
- Value (18)